Literature DB >> 25445848

Diabetes mellitus and severe mental illness: mechanisms and clinical implications.

Richard I G Holt1, Alex J Mitchell2.   

Abstract

The prevalence of diabetes mellitus is twofold to threefold higher in people with severe mental illness (SMI) than in the general population, with diabetes mellitus affecting ∼12% of people receiving antipsychotics. The consequences of diabetes mellitus are more severe and frequent in people with SMI than in those without these conditions, with increased rates of microvascular and macrovascular complications, acute metabolic dysregulation and deaths related to diabetes mellitus. Multiple complex mechanisms underlie the association between diabetes mellitus and SMI; these mechanisms include genetic, environmental and disease-specific factors, and treatment-specific factors. Although antipsychotics are the mainstay of treatment in SMI, a causative link, albeit of uncertain magnitude, seems to exist between antipsychotics and diabetes mellitus. The principles of managing diabetes mellitus in people with SMI are similar to those for the general population and should follow currently established treatment algorithms. Lifestyle interventions are needed to reduce incident diabetes mellitus. In addition, improved uptake of opportunities to screen for this disease will reduce the high prevalence of undiagnosed diabetes mellitus. Currently, people with SMI receive poorer treatment for diabetes mellitus than the general population. Thus, health-care professionals in primary care, diabetes mellitus services and mental health teams have a responsibility to ensure that patients with SMI are not disadvantaged.

Entities:  

Mesh:

Year:  2014        PMID: 25445848     DOI: 10.1038/nrendo.2014.203

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  117 in total

Review 1.  The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders.

Authors:  Roger S McIntyre; Mohammad Alsuwaidan; Benjamin I Goldstein; Valerie H Taylor; Ayal Schaffer; Serge Beaulieu; David E Kemp
Journal:  Ann Clin Psychiatry       Date:  2012-02       Impact factor: 1.567

Review 2.  Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.

Authors:  Lawrence Maayan; Julia Vakhrusheva; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

3.  Immunological characteristics of diabetes in schizophrenia.

Authors:  Dan Cohen; M R Batstra; C C Gispen-de Wied
Journal:  Diabetologia       Date:  2005-07-29       Impact factor: 10.122

4.  Association of psychiatric illness and obesity, physical inactivity, and smoking among a national sample of veterans.

Authors:  Lydia A Chwastiak; Robert A Rosenheck; Lewis E Kazis
Journal:  Psychosomatics       Date:  2011 May-Jun       Impact factor: 2.386

Review 5.  The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.

Authors:  Josep Maria Haro; Luis Salvador-Carulla
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 6.  Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

Authors:  Marc De Hert; Weiping Yu; Johan Detraux; Kim Sweers; Ruud van Winkel; Christoph U Correll
Journal:  CNS Drugs       Date:  2012-09-01       Impact factor: 5.749

7.  A UK audit of screening for the metabolic side effects of antipsychotics in community patients.

Authors:  Thomas R E Barnes; Carol Paton; Mary-Rose Cavanagh; Elizabeth Hancock; David M Taylor
Journal:  Schizophr Bull       Date:  2007-05-04       Impact factor: 9.306

8.  Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia.

Authors:  Ganesan Venkatasubramanian; Seetharamaiah Chittiprol; Narendran Neelakantachar; Magadi N Naveen; Jagadisha Thirthall; Bangalore N Gangadhar; K Taranath Shetty
Journal:  Am J Psychiatry       Date:  2007-10       Impact factor: 18.112

Review 9.  Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies.

Authors:  Ghazaleh Valipour; Parvane Saneei; Ahmad Esmaillzadeh
Journal:  J Clin Endocrinol Metab       Date:  2014-07-22       Impact factor: 5.958

10.  Fetal growth restriction and the development of major depression.

Authors:  H-M Vasiliadis; S E Gilman; S L Buka
Journal:  Acta Psychiatr Scand       Date:  2008-04       Impact factor: 6.392

View more
  32 in total

1.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

2.  Effect of a Behavioral Weight Loss Intervention in People With Serious Mental Illness and Diabetes.

Authors:  Eva Tseng; Arlene T Dalcin; Gerald J Jerome; Joseph V Gennusa; Stacy Goldsholl; Courtney Cook; Lawrence J Appel; Nisa M Maruthur; Gail L Daumit; Nae-Yuh Wang
Journal:  Diabetes Care       Date:  2019-02-14       Impact factor: 19.112

Review 3.  Type 2 diabetes in children and adolescents on atypical antipsychotics.

Authors:  Pornpoj Pramyothin; Lalita Khaodhiar
Journal:  Curr Diab Rep       Date:  2015-08       Impact factor: 4.810

Review 4.  Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews.

Authors:  Nanna Lindekilde; Stine H Scheuer; Femke Rutters; Lenette Knudsen; Mathias Lasgaard; Katrine H Rubin; Jan Erik Henriksen; Mika Kivimäki; Gregers S Andersen; Frans Pouwer
Journal:  Diabetologia       Date:  2021-11-29       Impact factor: 10.122

Review 5.  Psychological interventions for treating foot ulcers, and preventing their recurrence, in people with diabetes.

Authors:  Helen McGloin; Declan Devane; Caroline D McIntosh; Kirsty Winkley; Georgina Gethin
Journal:  Cochrane Database Syst Rev       Date:  2021-02-08

6.  Health Care and Mortality among Persons with Severe Mental Illness.

Authors:  Gilad Gal; Hanan Munitz; Itzhak Levav
Journal:  Can J Psychiatry       Date:  2016-09-24       Impact factor: 4.356

7.  Polygenic risk for type 2 diabetes mellitus among individuals with psychosis and their relatives.

Authors:  Jaya L Padmanabhan; Pranav Nanda; Neeraj Tandon; Suraj S Mothi; Nicolas Bolo; Steven McCarroll; Brett A Clementz; Elliot S Gershon; Godfrey D Pearlson; John A Sweeney; Carol A Tamminga; Matcheri S Keshavan
Journal:  J Psychiatr Res       Date:  2016-02-23       Impact factor: 4.791

Review 8.  A network analysis framework of genetic and nongenetic risks for type 2 diabetes.

Authors:  Yuan Zhang; Shu Li; Zhi Cao; Yangyang Cheng; Chenjie Xu; Hongxi Yang; Li Sun; Hongxiao Jiao; Ju Wang; Wei-Dong Li; Yaogang Wang
Journal:  Rev Endocr Metab Disord       Date:  2020-09-14       Impact factor: 6.514

9.  Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries.

Authors:  Masuma Pervin Mishu; Eleonora Uphoff; Faiza Aslam; Sharad Philip; Judy Wright; Nilesh Tirbhowan; Ramzi A Ajjan; Zunayed Al Azdi; Brendon Stubbs; Rachel Churchill; Najma Siddiqi
Journal:  Cochrane Database Syst Rev       Date:  2021-02-16

10.  Association of Low-Dose Quetiapine and Diabetes.

Authors:  Mikkel Højlund; Lars C Lund; Kjeld Andersen; Christoph U Correll; Jesper Hallas
Journal:  JAMA Netw Open       Date:  2021-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.